TIME |
AGENDA |
PRESENTERS |
ROOM |
7:00-8:00am |
ICRN Meeting |
By Invitation Only |
Alta, Snowbird, Brighton (2nd Floor) |
7:00-8:00am |
EPIC |
By Invitation Only |
Park City (2nd Floor) |
8:00-8:05am |
Welcome to Conference/Foundation Update |
Stacie Lindsey |
Salons A-E |
8:05-8:10am |
Conference Welcome and Overview from Conference Chairs |
Nabeel Bardeesy, MGH Katie Kelley, UCSF |
Salons A-E |
8:10-8:30am |
Incidence of Cholangiocarcinoma: A Disease on the Rise |
Jessica Petrick, NIH |
Salons A-E |
8:30-8:50am |
Global Risk Factors for Cholangiocarcinoma |
Ruben Hernaez, Baylor |
Salons A-E |
8:50-9:10am |
Practice Patterns and Outcomes from a Real-World Cholangiocarcinoma Database |
Kyu-Pyo Kim, ASAN, Korea |
Salons A-E |
9:10-9:25am |
Panel Discussion |
Petrick, Hernaez, Kim |
Salons A-E |
9:25-9:40am |
ICRN Update |
Milind Javle, MD Anderson |
Salons A-E |
9:40-9:45am |
Patient Perspective |
Michelle Clayton |
Salons A-E |
9:45-10:00am |
Break |
|
Salons F-J |
10:00-10:30am |
Genomics of Cholangiocarcinoma: Association with Anatomical Subtype, Risk Factors, and Geography |
Bin Teh, Cancer Science Institute, Singapore |
Salons A-E |
10:30-10:50am |
Developments in Molecular Pathology: Precursor Lesions |
Vikram Deshpande, MGH |
Salons A-E |
10:50-11:20am |
FGFR Signaling as a Therapeutic Target |
Peter Hammerman, Novartis |
Salons A-E |
11:20-11:35am |
Understanding Response and Resistance to FGFR Inhibition in Clinical Trials |
Lipika Goyal, MGH |
Salons A-E |
11:35-11:45am |
Targeting the Hippo Pathway in Cholangiocarcinoma |
John Gordan, UCSF |
Salons A-E |
11:45am-12:00pm |
Panel Discussion |
Teh, Deshpande, Hammerman, Goyal, Gordan |
Salons A-E |
12:00-2:00pm |
Lunch |
|
Salons F-J |
12:00-2:00pm |
Industry Forum |
By Invitation Only |
Brighton (2nd Floor) |
12:00-1:00pm |
CholangioConnect Meeting |
By Invitation Only |
Cottonwood |
1:00-2:00pm |
Volunteer Meeting - All Welcome |
|
Salons A-E |
1:00-2:00pm |
PCORI Advisory Board Meeting |
By Invitation Only |
Park City (2nd Floor) |
2:00-2:30pm |
Metabolic Liabilities of IDH Mutant Cancer Cells |
William Kaelin, Dana-Farber Cancer Institute |
Salons A-E |
2:30-3:00pm |
Results of IDH Inhibitor Trials and Correlative Science |
Bin Wu, Agios |
Salons A-E |
3:00-3:20pm |
Molecular Subtyping of Cholangiocarcinoma Links IDH Mutations and Altered Mitochondrial Biogenesis |
Lewis Roberts, Mayo Clinic |
Salons A-E |
3:20-3:35pm |
Panel Discussion |
Kaelin, Wu, Roberts |
Salons A-E |
3:35-3:50pm |
Break |
|
Salons F-J |
3:50-4:20pm |
A Distributed Hepatocyte Subpopulation Repopulates the Liver in Homeostasis and Injury |
Steve Artandi, Stanford |
Salons A-E |
4:20-4:50pm |
Next-Generation Mouse Model of Hepatobiliary Cancer |
Scott Lowe, Cold Spring Harbor Lab |
Salons A-E |
4:50-5:20pm |
Mitochondrial Dysfunction, Inflammation, and Cholangiocarcinoma |
Matthias Heikenwalder, German Cancer Research Center, Heidelberg |
Salons A-E |
5:20-5:50pm |
Immunotherapy in Hepatobiliary Cancer |
Tim Greten, NIH |
Salons A-E |
5:50-6:00pm |
Hippo Signaling Pathway |
Andrea McClatchey, MD, Massachusetts General Hospital Cancer Center |
Salons A-E |
6:00-7:00pm |
Dinner |
|
Salons F-J |
7:00-9:00pm |
Poster Session / Networking |
|
Salons F-J |